Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

Allahyari, Abolghasem; Ehsanpour, Ali; Najafi, Behrouz; Ansarinejad, Nafseh; Mehrzad, Valiollah; Kalantari, Behjat; Raafat, Jahangir; Ghadiany, Mojtaba; Shahi, Farhad; Gharib, Behrooz; Moazed, Vahid; Khosravi, Adnan; Mirpour, Mir Hossein; Salari, Sina; Mortazavizadeh, Seyedmohammadreza; Nekoyi, Amirabbas; Khani, Mohsen; Sadeghi, Alireza; Gharib, Sirus; Bary, Alireza; Mirzania, Mehrzad; Haghighat, Shirin; Razavi, Seyed Mohsen; Emami, Seyed Amir Hossein; Hosseinzadeh, Mehran; Mirbolouk, Mahdi; Sadighi, Sanambar; Shahrasbi, Abdolali; Esfahani, Ali; Gity, Masoumeh; Anjidani, Nassim; Kaf, Hamidreza; Najaf, Safa

doi:10.1186/s12885-022-10455-0

BMC Cancer

Article metrics
Last updated: Sat, 27 Apr 2024 1:55:51 Z

Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

Access & Citations

855

Article Accesses
0

Web of Science
0

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com